Stanford Center for Urologic Genomics
The Stanford University School of Medicine has a long history of contributing to the understanding of benign and malignant urologic diseases. Stanford investigators have carried out foundational studies in urinary tract infections in adults and children, prostatitis and pelvic pain syndromes in men, painful bladder and interstitial cystitis, calculus disease and urologic malignancies. The emergence of new tools and paradigms, particularly in genomic medicine, opens new opportunities for fundamentally understanding benign urologic diseases, generating a molecular classification of benign diseases, and devising new therapeutic approaches.
The Stanford Center for Urologic Genomics was established with a P20 development grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The broad vision of the Center is to apply the concepts and practices of precision medicine to lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH). The Center brings together a multidisciplinary team of researchers and clinicians with diverse expertise and experience. The long-term objective is to reduce the burden of LUTS, through activities of the Center’s Scientific Research Project and Educational Enrichment Program.